Feasibility of Sentinel Cerebral Embolic Protection Device Deployment During Transfemoral Transcatheter Aortic Valve Replacement

Cerebral embolic protection has emerged as a preventive measure for procedural stroke in transcatheter aortic valve replacement (TAVR).1 The Sentinel System (Boston Scientific Corp. Boston, Massachusetts), a 2-filter debris-capturing system, has been the only commercially available protection device in the United States since its approval by the Food and Drug Administration in 2017. In the Sentinel trial, the largest randomized trial (n  = 363) so far, the device was successfully deployed in 94.7% of patients.

Source: The American Journal of Cardiology - October 1, 2022 Category: Cardiology Authors: Toshiaki Isogai, Husitha Reddy Vanguru, Amar Krishnaswamy, Ankit Agrawal, Nikolaos Spilias, Shashank Shekhar, Anas M. Saad, Beni Rai Verma, Rishi Puri, Grant W. Reed, Zoran B. Popovi ć, Shinya Unai, James J. Yun, Ken Uchino, Samir R. Kapadia Source Type: research